The Nm23-H1 metastasis suppressor as a translational target
Authors:
- Jean-Claude MarshallJMJean-Claude Marshall
- Joshua CollinsJCJoshua Collins
- Natascia MarinoNMNatascia Marino
- Patricia SteegPSPatricia Steeg
- 1 May 2010
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 46 (7) , 1278-1282
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Clinical-Translational Approaches to the Nm23-H1 Metastasis SuppressorClinical Cancer Research, 2008
- Tumor‐vascular interactions and tumor dormancyAPMIS, 2008
- Aldolase C‐positive cerebellar Purkinje cells are resistant to delayed death after cerebral trauma and AMPA‐mediated excitotoxicityEuropean Journal of Neuroscience, 2007
- Multicenter Phase II Study of Fertility-Sparing Treatment With Medroxyprogesterone Acetate for Endometrial Carcinoma and Atypical Hyperplasia in Young WomenJournal of Clinical Oncology, 2007
- The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastasesProceedings of the National Academy of Sciences, 2006
- Medroxyprogesterone Acetate Elevation of Nm23-H1 Metastasis Suppressor Expression in Hormone Receptor–Negative Breast CancerJNCI: Journal of the National Cancer Institute, 2005
- Nm23-H1 Metastasis Suppressor Expression Level Influences the Binding Properties, Stability, and Function of the Kinase Suppressor of Ras1 (KSR1) Erk Scaffold in Breast Carcinoma CellsMolecular and Cellular Biology, 2005
- Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancerCancer Letters, 2003
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002